For most pharmaceutical companies, developing a medicine for a single patient would seem like commercial madness. However, Perth biotechnology player Syngenis Labs is helping turn that conventional wisdom on its head. It has joined forces with two Western Australian medical research giants to advance treatments for children with rare genetic diseases, sometimes so rare that only one patient may need the medicine.

The company has teamed up with the WA-based Perron Institute and the Personalised Medicine Centre (PMC), a joint initiative between Perron and Murdoch University, to establish a specialised preclinical safety-testing platform for…

Read the full article at SMH.COM.AU